Important noticeWe would like to inform you that Chinese Journal of Cancer has changed the title to Cancer Communications on 1st March 2018.
Please click the links below for more information of Cancer Communications https://cancercommun.biomedcentral.com
|
pISSN: 1000-467X eISSN: 1944-446X CN: 44-1195/R |
New articles accepted recently Volume 36 Issue 12 From January 2002 |
Editorial announcement regarding title change of Chinese Journal of Cancer to Cancer Communications
Chinese Journal of Cancer获评“2017中国最具国际影响力学术期刊”
CJC's SCI Impact Factor reaches 4.111 in 2016
The 4th Guangzhou International Symposium on Oncology Held
We are pleased to announce that the first Impact Factor of CJC is 2.155
U.S. Chinese Anti-Cancer Association-Asia Fund for Cancer Research 2015 Scholar Awards
巧用PowerPoint制作和修改医学论文图片——编辑部业务学习会整理
The New Horizons in Cancer Research Conference of AACR ended successfully in Shanghai
The Chinese Journal of Cancer is indexed in Science Citation Index (SCI) Expanded
CJC wins the title of the 2012' Excellent International Impact Academic Journal of China
Gastric cancer |
|
Edited by Yun Dai and Li Yan |
This thematic series discusses the molecular classifications of gastric cancer by the Cancer Genome Atlas (TCGA) and the Asian Cancer Research Group (ACRG) as well as the implications in personalized therapeutic choices; discusses the evolution of gastric surgery and presents perspectives on surgical techniques in treating gastric cancer; and reviews current and emerging targeted agents as well as immunotherapies in treating gastric cancer. With these advancements in molecular characterization, surgical intervention, and targeted and immunotherapies, gastric cancer will enter a personalized medicine era in the next 5 years.
|
- - - - - - - - - - - - - - - - - - - - - - - - - - - -
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
Tumor angiogenesis |
|
Edited by Francesco Pezzella
|
Forming efficient vasculature network, also known as tumor angiogenesis, is a critical hallmark in tumor development. Explorations on its underlying molecular mechanisms have resulted in several novel anti-cancer drugs. However, the modest survival benefits from anti-angiogenic therapy have forced us to revisit our understanding on tumor angiogenesis. In this special issue, world-leading experts have contributed their critical thoughts to reveal alternative tumor angiogenesis approaches and potential treatment targets.
|
- - - - - - - - - - - - - - - - - - - - - - - - - - - -
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - Lung cancer |
|
 Edited by Lin Yan and Wei Zhang
|
Lung cancer accounts for approximately 21% of worldwide cancer deaths and a staggering 1.6 million new cases are diagnosed every year. In China, lung cancer has become a particularly challenging disease because of air pollution and smoking. This thematic series discusses the proper use of targeted agents in treating lung cancer, reviews the application of biomarkers in clinical management and drug development, and analyzes the unique challenges in developing novel drugs for lung cancer in China.
|
CJC is now published by BioMed Central
© Chinese Journal of Cancer
ICP 备案序号:粤ICP备12079158号
Sun Yat-sen University Cancer Center
651 Dongfeng Road East,Guangzhou 510060, P.R.China
